Urgent cares earn over $400 million from COVID-19 testing
October 1, 2020 -- With approximately 10,000 urgent care locations across the country and more than three-fourths of the U.S. population residing within a 10-minute drive of one, the urgent care market is expected to grow, writes Bruce Carlson of Kalorama Information, a sister company of LabPulse.com.
Discuss
October 1, 2020 -- With approximately 10,000 urgent care locations across the country and more than three-fourths of the U.S. population residing within a 10-minute drive of one, the urgent care market is expected to grow, writes Bruce Carlson of Kalorama Information, a sister company of LabPulse.com.
Discuss PerkinElmer newborn screening test gets CE Mark
September 30, 2020 -- PerkinElmer has received the CE Mark for its reverse transcription polymerase chain reaction newborn screening assay.
September 30, 2020 -- PerkinElmer has received the CE Mark for its reverse transcription polymerase chain reaction newborn screening assay.
FDA issues EUA for OralDNA's oral rinse COVID-19 test
September 30, 2020 -- The U.S. Food and Drug Administration (FDA) has issued an emergency use authorization (EUA) for OraRisk, a saline oral rinse COVID-19 test from OralDNA Labs. OraRisk is a reverse transcription polymerase chain reaction test that is the first saline 30-second swish and gargle collection COVID-19 test to get an EUA.
September 30, 2020 -- The U.S. Food and Drug Administration (FDA) has issued an emergency use authorization (EUA) for OraRisk, a saline oral rinse COVID-19 test from OralDNA Labs. OraRisk is a reverse transcription polymerase chain reaction test that is the first saline 30-second swish and gargle collection COVID-19 test to get an EUA.
Biovica files 510(k) submission for breast cancer test
September 25, 2020 -- Biovica has filed a 510(k) submission with the U.S. Food and Drug Administration for its DiviTumTKa breast cancer test.
September 25, 2020 -- Biovica has filed a 510(k) submission with the U.S. Food and Drug Administration for its DiviTumTKa breast cancer test.
Study finds SARS-CoV-2 antibody kits have varying accuracy
September 25, 2020 -- Commercial SARS-CoV-2 antibody testing kits have a wide variation in sensitivity and specificity, according to a U.K. study published September 24 in PLOS Pathogens.
September 25, 2020 -- Commercial SARS-CoV-2 antibody testing kits have a wide variation in sensitivity and specificity, according to a U.K. study published September 24 in PLOS Pathogens.
Quadrant wins EUA for COVID-19 saliva test
September 24, 2020 -- Quadrant Biosciences has received emergency use authorization (EUA) from the U.S. Food and Drug Administration for its Clarifi COVID-19 test kit.
September 24, 2020 -- Quadrant Biosciences has received emergency use authorization (EUA) from the U.S. Food and Drug Administration for its Clarifi COVID-19 test kit.
United Airlines launches pilot COVID-19 testing program
September 24, 2020 -- United Airlines has announced a pilot COVID-19 testing program for travelers in which customers traveling on United from San Francisco International Airport to Hawaii will have the option of taking a rapid COVID-19 test at the airport or a self-collected, mail-in test ahead of the trip.
September 24, 2020 -- United Airlines has announced a pilot COVID-19 testing program for travelers in which customers traveling on United from San Francisco International Airport to Hawaii will have the option of taking a rapid COVID-19 test at the airport or a self-collected, mail-in test ahead of the trip.
Promega to further develop OncoMate MSI assay
September 22, 2020 -- Promega announced that it plans to further develop its OncoMate microsatellite instability (MSI) assay as a companion diagnostic test for Incyte's anti-PD-1 drug candidate for endometrial cancer, retifanlimab.
September 22, 2020 -- Promega announced that it plans to further develop its OncoMate microsatellite instability (MSI) assay as a companion diagnostic test for Incyte's anti-PD-1 drug candidate for endometrial cancer, retifanlimab.
Holy Grail: Ilumina nabs cancer testing firm in $8B deal
September 21, 2020 -- Illumina has agreed to acquire cancer diagnostics startup Grail for $8 billion in cash and stock. Grail utilizes Illumina's next-generation sequencing (NGS) technology, data science, and machine learning to identify cancer signals in blood samples.
September 21, 2020 -- Illumina has agreed to acquire cancer diagnostics startup Grail for $8 billion in cash and stock. Grail utilizes Illumina's next-generation sequencing (NGS) technology, data science, and machine learning to identify cancer signals in blood samples.
Hoth, GW partner to develop mobile COVID-19 test
September 21, 2020 -- Clinical-stage biopharmaceutical company Hoth Therapeutics and George Washington University (GW) have partnered to create a device that allows health professionals to diagnose COVID-19 with a mobile device.
September 21, 2020 -- Clinical-stage biopharmaceutical company Hoth Therapeutics and George Washington University (GW) have partnered to create a device that allows health professionals to diagnose COVID-19 with a mobile device.